Design of a Multicenter, Randomized Controlled Trial for the Treatment of Peripheral Neuropathic Pain (COMFORT Study) with a Micro-Implantable Pulse Generator

• Published in: Journal of pain research 2024-01, Vol.17, p.2891-2901
• Main Authors: Hatheway, John, Hersel, Alexander Perry, Song, Jonathan, Engle, Mitchell P, Gutierrez, Genaro, Khemlani, Vishal, Kapural, Leonardo, Moore, Gregory, Ajakwe, Reginald Chinaedu, Trainor, Drew M, Hah, Jennifer M, Staats, Peter, Lynch, Paul, Makous, James, Heit, Gary, Kottalgi, Shilpa, Desai, Mehul J
• Format: Article
• Language: English
• Subjects: Batteries; battery-free; Care and treatment; Chronic pain; Clinical trials; Comparative analysis; Health aspects; Implants, Artificial; micro-ipg; neuralgia; neuropathy; Pain; peripheral nerve stimulation; pns; Prosthesis; Study Protocol
• ISSN: 1178-7090; 1178-7090
• DOI: 10.2147/JPR.S460563

Peripheral Nerve Stimulation (PNS) is an established therapy for chronic neuropathic pain of peripheral origin, typically following nerve injury. However, there is a paucity of Randomized Controlled Trials (RCTs) demonstrating the therapeutic benefits of PNS. The goals of the current study (COMFORT Study) are to document the safety and efficacy of the Nalu Neurostimulation in a PNS RCT, compared to conventional medical management (CMM). This is a prospective, multicenter, RCT evaluating the treatment of neuropathic pain with PNS therapy. One of the following four regions will be targeted for treatment: low back, shoulder, knee or foot/ankle. Consented subjects will undergo a baseline evaluation, after which they are randomized 2:1 (PNS+CMM arm to CMM arm). Subjects randomized to PNS+CMM arm will undergo a trial implant period using best clinical practices. Subjects who pass the trial phase, by showing a ≥ 50% reduction in pain relative to baseline, will receive the permanent implant. All subjects receiving a permanent implant will be followed for a total of 36 months. At the 3-month primary end point, subjects in CMM arm will be given the option to crossover into PNS+CMM arm, beginning with a trial implant. The study duration is expected to be 5.5 years from first enrollment to last follow-up of last subject and subsequent study closure. Adverse events will be captured throughout the study. The COMFORT study, described here, has the potential to demonstrate the efficacy and safety of the Nalu Neurostimulation System in the treatment of peripheral neuropathy. Results of this study will be the first Level-I evidence, out to 36 months, validating the use of this PNS system in the treatment of chronic pain. This study is designed to enroll the largest cohort, to date, of subjects comparing PNS+CMM vs CMM alone.